1. Home
  2. FBIO vs ADCT Comparison

FBIO vs ADCT Comparison

Compare FBIO & ADCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Fortress Biotech Inc.

FBIO

Fortress Biotech Inc.

HOLD

Current Price

$3.37

Market Cap

113.6M

Sector

Health Care

ML Signal

HOLD

Logo ADC Therapeutics SA

ADCT

ADC Therapeutics SA

HOLD

Current Price

$1.34

Market Cap

136.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBIO
ADCT
Founded
2006
2011
Country
United States
Switzerland
Employees
78
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
113.6M
136.1M
IPO Year
N/A
2019

Fundamental Metrics

Financial Performance
Metric
FBIO
ADCT
Price
$3.37
$1.34
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
4
Target Price
$17.00
$7.75
AVG Volume (30 Days)
611.0K
1.5M
Earning Date
05-15-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
30.86
EPS
N/A
N/A
Revenue
N/A
$81,357,000.00
Revenue This Year
$55.22
N/A
Revenue Next Year
$40.55
$66.49
P/E Ratio
N/A
N/A
Revenue Growth
N/A
14.85
52 Week Low
$1.77
$0.78
52 Week High
$4.53
$4.98

Technical Indicators

Market Signals
Indicator
FBIO
ADCT
Relative Strength Index (RSI) 58.98 43.09
Support Level $3.28 $0.78
Resistance Level $3.80 $1.44
Average True Range (ATR) 0.22 0.11
MACD 0.03 0.09
Stochastic Oscillator 59.46 75.00

Price Performance

Historical Comparison
FBIO
ADCT

About FBIO Fortress Biotech Inc.

Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.

About ADCT ADC Therapeutics SA

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's FDA-approved and marketed product, ZYNLONTA (loncastuximab tesirine), is a CD19-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy. Additionally, the company's development pipeline comprises LOTIS-2, LOTIS-5, LOTIS-7, and ADCT-241, being developed as potential therapies for different cancer diseases. Geographically, the firm generates maximum revenue from the United States, followed by Europe, the Middle East and Africa (EMEA).

Share on Social Networks: